Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux

About this trial

Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (CSC)) mechanisms. CSC are able to circulate within blood, protected from destruction by immunosuppressive cells such as MDSC. Some factors such as G-CSF, administered to lower febrile neutropenia, should modulate properties of MDSC and CSC, but data are contradictory, and literature remain poor regarding its effects on the interactions between MDSC and CSC in blood clusters. Indeed, this project aims at better characterizing the effect of G-CSF on these interactions and on their functions in NSCLC patients receiving G-CSF.

Eligibility criteria

Qualifiers

Patients (male or female) aged ≥ 18 years

Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy

Receiving chemotherapy and immunotherapy as first-line treatment

Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)

Disqualifiers

Patient with a small cell lung carcinoma

Non-metastatic disease

Actionable mutation or genomic alteration in EGFR, ALK or ROS1

Corticosteroids > 10 mg/j

Trial design

Treatments tested in this trial

  • Blood sample

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators